

Get ready for your next step



This guide will help you learn more about Aliqopa, including what to expect while taking Aliqopa and how to prepare for the next step in your treatment plan.

What is ALIQOPA™?

ALIQOPA is a prescription therapy used to treat adults with follicular lymphoma (FL) when the disease has come back after treatment with at least two prior medicines.

ALIQOPA went through a faster FDA approval process because of how it caused FL tumors to shrink. Data gathered from an additional trial may be needed for continued approval of its current use.

It is not known if ALIQOPA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Aliqopa can cause serious side effects, including:

Infections: ALIQOPA can cause serious infections that may lead to death. The most common serious infection was pneumonia. Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with ALIQOPA.

Please see additional Important Safety Information throughout this brochure, and [click here](#) for the Consumer Brief Summary of full Prescribing Information.

Starting your journey with Aliqopa™



Whether your doctor has prescribed you Aliqopa or is thinking about adding it to your treatment plan, this guide will provide you with important information about the treatment, including:

- What Aliqopa is
- How Aliqopa works
- How Aliqopa is given
- How to prepare for an Aliqopa treatment cycle
- What to do if you have side effects while taking Aliqopa

If you have any questions about treatment with Aliqopa, make sure to speak with a member of your healthcare team.



Aliqopa is a treatment for relapsed* follicular lymphoma that is not chemotherapy

Aliqopa was studied in 104 patients with follicular lymphoma. In the clinical study for Aliqopa, all of the patients with follicular lymphoma had already received at least 2 prior medicines. The study measured whether Aliqopa worked, by looking at the percentage of patients whose tumors shrank within a certain period of time in response to treatment with Aliqopa, also known as the *overall response rate*.

*To be in the study, patients had to experience a *relapse*, which means that follicular lymphoma, or the signs and symptoms of follicular lymphoma, had returned after a period of improvement.

Aliqopa was studied as a *monotherapy*. This means that Aliqopa was studied alone without any other medicines.

Aliqopa was studied in patients with follicular lymphoma who were similar to you.

Please see Important Safety Information throughout this brochure, and [click here](#) for the Consumer Brief Summary of full Prescribing Information.

What were the results of the study for Aliqopa™?

Most patients experienced tumor shrinkage with Aliqopa

IN THE STUDY, **59%** OF PATIENTS TAKING ALIQOPA HAD A RESPONSE* TO THE TREATMENT.

This means that about **3 out of 5 patients** responded to treatment with Aliqopa.

Patients experienced 1 of 2 different types of response

14% experienced a **complete response**, which means the tumor went away completely

44% experienced a **partial response**, which means the tumor shrank significantly

*Response rate is a term used for the portion of patients whose tumor shrank within a certain period of time.


In the Aliqopa clinical study of 104 patients with follicular lymphoma who had already received at least 2 prior treatments, most patients experienced tumor shrinkage with Aliqopa.

ALIQOPA can cause serious side effects, including (cont'd):


High blood sugar (hyperglycemia): High blood sugar is common following ALIQOPA infusion and can sometimes be serious. Tell your healthcare provider if you develop any symptoms of hyperglycemia during treatment with ALIQOPA. Symptoms of hyperglycemia may include being very hungry, being very thirsty, frequent urination and headaches.

Please see Important Safety Information throughout this brochure, and [click here](#) for the Consumer Brief Summary of full Prescribing Information.

The median time† it took for the tumor to begin to shrink was **1.7 MONTHS**
Range: 1.3 to 9.7 months



Patients continued to experience tumor shrinkage for a median time† of **12.2 MONTHS**
Range: 0+ to 22.6 months



†The *median* time is the middle number of a number set. In other words, half of the patients experienced numbers above the median and half of the patients experienced numbers below the median.

In this study, Aliqopa was shown to help patients with follicular lymphoma.

How does Aliqopa™ work?

Aliqopa interferes with the signaling that causes cancer growth

Aliqopa is not chemotherapy. It mainly targets 2 important proteins in cancerous B cells (PI3K* alpha and PI3K delta). These proteins can help the growth of cancer cells and that action needs to be stopped.


When lymphoma is left untreated, cell receptors send signals within the cell to these proteins that tell the cancer to multiply and spread. Aliqopa prevents the signal from reaching the proteins, which helps prevent the cancer cells from growing.

Aliqopa was studied as a monotherapy. This means that patients were treated with only Aliqopa for their follicular lymphoma.

*Phosphatidylinositol 3-kinase
(fos-fa-TIDE-ill-in-NO-sit-all three KINE-ace)



B cell receptor



By mainly targeting these 2 proteins, Aliqopa may kill lymphoma cells and stop them from multiplying and spreading. During this process, Aliqopa may also impact healthy cells and tissues surrounding the lymph nodes.

Please see Important Safety Information throughout this brochure, and [click here](#) for the Consumer Brief Summary of full Prescribing Information.

How is treatment with Aliqopa™ given?

Aliqopa is a 1-hour intravenous (IV) infusion given to you by a healthcare provider

Only 3 days of treatment for every 4-week cycle

Usually given on Days **1 8 15** of a 28-day cycle

1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28

- You will receive your treatment with Aliqopa 1 time every week for 3 weeks and then stop for 1 week. This is 1 cycle of treatment. Aliqopa is usually given on Day 1, Day 8, and Day 15 of a 28-day treatment cycle
- Your healthcare provider will decide how many treatment cycles you need. It is important to stay on scheduled cycles to get the most out of your treatment with Aliqopa
- Your healthcare provider may withhold treatment, decrease your dose, temporarily stop treatment, or permanently stop treatment with Aliqopa if you have certain side effects



Aliqopa is given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day treatment cycle.

Please see Important Safety Information throughout this brochure, and [click here](#) for the Consumer Brief Summary of full Prescribing Information.

What should I tell my healthcare provider before receiving Aliqopa™?

It's important to tell your healthcare provider about all of your medical conditions, including if you



have an infection



have lung or breathing problems



have high blood pressure (hypertension)



have diabetes or high blood sugar (hyperglycemia)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ALIQOPA works. Avoid taking St. John's Wort or drinking grapefruit juice during treatment with ALIQOPA.

It's important to tell your healthcare provider about all of your medical conditions, including if you (cont'd)



are pregnant or plan to become pregnant. Aliqopa can harm your unborn baby.

- Your healthcare provider will perform a pregnancy test before starting treatment with Aliqopa
- **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with Aliqopa and for 1 month after the last dose of Aliqopa. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with Aliqopa
- **Males** with female partners who are able to become pregnant should use effective birth control (contraception) during treatment with Aliqopa and for 1 month after the last dose of Aliqopa



are breastfeeding or plan to breastfeed. It is not known if Aliqopa passes into your breast milk. Do not breastfeed during treatment with Aliqopa and for 1 month after the last dose of Aliqopa. Talk to your healthcare provider about the best way to feed your child during treatment with Aliqopa

Please see additional Important Safety Information throughout this brochure, and [click here](#) for the Consumer Brief Summary of full Prescribing Information.

Important Safety Information

Aliqopa can cause serious side effects, including:

Infections: ALIQOPA can cause serious infections that may lead to death. The most common serious infection is pneumonia. Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with ALIQOPA.

High blood sugar (hyperglycemia): High blood sugar is common following ALIQOPA infusion and can sometimes be serious. Tell your healthcare provider if you develop any symptoms of hyperglycemia during treatment with ALIQOPA. Symptoms of hyperglycemia may include being very hungry, being very thirsty, frequent urination and headaches.

High blood pressure (hypertension): High blood pressure is common following ALIQOPA infusion and can sometimes be serious.

Lung or breathing problems: Your healthcare provider may do tests to check your lungs if you have breathing problems during treatment with ALIQOPA. Tell your healthcare provider right away if you develop new or worsening cough, shortness of breath, or difficulty breathing.

Low white blood cell count (neutropenia): Neutropenia is common with ALIQOPA treatment and can sometimes be serious. Your healthcare provider will check your blood counts at least weekly during treatment with ALIQOPA. Tell your healthcare provider right away if you have a fever or any signs of infection during treatment with ALIQOPA.

Severe skin reactions: Skin peeling, rash, and itching are common with ALIQOPA and can sometimes be serious. Tell your healthcare provider if you develop skin peeling, itching, or rash during treatment with ALIQOPA. Your healthcare provider may withhold treatment, decrease your dose, or permanently stop treatment if you develop severe skin reactions during treatment with ALIQOPA.

Before receiving ALIQOPA, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection
 - have lung or breathing problems
 - have high blood pressure (hypertension)
 - have diabetes or high blood sugar (hyperglycemia)
 - are pregnant or plan to become pregnant. ALIQOPA can harm your unborn baby.
- Your healthcare provider will perform a pregnancy test before starting treatment with ALIQOPA.

- **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with ALIQOPA and for 1 month after the last dose of ALIQOPA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with ALIQOPA.
- **Males** with female partners who are able to become pregnant should use effective birth control (contraception) during treatment with ALIQOPA and for 1 month after the last dose of ALIQOPA.
- are breastfeeding or plan to breastfeed. It is not known if ALIQOPA passes into your breast milk. Do not breastfeed during treatment with ALIQOPA and for 1 month after the last dose of ALIQOPA. Talk to your healthcare provider about the best way to feed your child during treatment with ALIQOPA.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ALIQOPA works.

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

What should I avoid while receiving ALIQOPA?

- Avoid taking St. John's Wort during treatment with ALIQOPA.
- Avoid drinking grapefruit juice during treatment with ALIQOPA.

The most common side effects of ALIQOPA include:

- low white blood cell count (leukopenia)
- low platelets in your blood (thrombocytopenia)
- diarrhea
- decreased strength and tiredness
- lower respiratory tract infection
- nausea

These are not all of the possible side effects of ALIQOPA. Call your healthcare provider for medical advice about side effects. You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

For important risk and use information about Aliqopa, [click here](#) to see the Consumer Brief Summary of full Prescribing Information on pages 22-25.

Remember to tell your healthcare team if you have any side effect that bothers you or that does not go away.

Tips to help manage potential Aliqopa™ side effects

Decreased energy



- **Stay active.** Engaging in light exercise may help keep up your energy level
- **Resting is important.** But remember that long naps during the day will make it harder to sleep at night
- **Prioritize.** Note the times that you have the most energy

Neutropenia (low white blood cell count)



- **Talk to your healthcare provider.** Your healthcare provider will be monitoring you for signs of neutropenia, which is a low white blood cell count. Talk to your healthcare provider about what symptoms to look out for
- **Take precautionary measures to avoid infections.** Wash your hands often, avoid raw foods, wear shoes outside and gloves for gardening, avoid hot tubs, and use a soft-bristle toothbrush
- **Note:** If you have neutropenia, don't change cat litter or pick up dog waste

Diarrhea/nausea



- **Alter your diet.** Consider the BRAT (bananas, rice, applesauce, toast) diet, which can help with gastrointestinal side effects
- **Decrease your portions.** Eat several small meals daily
- **Stay hydrated.** Drink lots of water throughout the day
- **Avoid irritants.** Try to stay away from spicy foods, alcohol, caffeine, and dairy products

Please see additional Important Safety Information throughout this brochure, and [click here](#) for the Consumer Brief Summary of full Prescribing Information.

High blood pressure and high blood sugar are common following Aliqopa infusion and typically return to normal after a few hours.

High blood pressure (hypertension)



- **High blood pressure** is common following Aliqopa infusion and can sometimes be serious
- For most patients, blood pressure levels typically peak within 2 hours after infusion and then go back to normal
- Your blood pressure may remain high for 6 to 8 hours after infusion with Aliqopa
- **Know your blood pressure.** Strive to keep it in the normal range. For example, a normal blood pressure rate is about 120/80 mmHg
- **Eat healthy.** Diets rich in whole grains, fruits, vegetables, and low-fat dairy are low in saturated fats and cholesterol
- **Exercise.** Talk to your doctor before starting any exercise program. Do not exercise if you have unrelieved pain, nausea/vomiting, or any other symptom that causes you concern
- **Limit alcohol consumption**
- **If you smoke,** try to quit

High blood sugar (hyperglycemia)



- **High blood sugar** is common following Aliqopa infusion and can sometimes be serious
- For most patients, blood sugar levels typically peak from 5 to 8 hours after infusion and then go back to normal
- Your blood sugar levels may remain high 1 day after infusion with Aliqopa
- **Know your numbers.** Get tested for diabetes and blood sugar levels
- **Eat healthy.** Eat fewer carbohydrates and eat more vegetables, fruits, and whole grains. Add healthy fats to your diet, such as avocado, salmon, and walnuts
- **Exercise.** Talk to your doctor before starting any exercise program. Do not exercise if you have unrelieved pain, nausea/vomiting, or any other symptom that causes you concern

What do I need to know before each infusion of Aliqopa™?

Blood sugar levels:

- Talk to your healthcare provider about what blood sugar levels are appropriate for you before and after starting Aliqopa
- Your infusion with Aliqopa may result in temporary high blood sugar
- For most patients, blood sugar levels typically peak from 5 to 8 hours after infusion and then return to normal. Blood sugar levels remained elevated in some patients 1 day after treatment

Blood pressure levels:

- Work with your healthcare provider to ensure your blood pressure levels are under control. Strive to keep it in the “normal” range, which is usually 120/80 mmHg or lower
- Your infusion may result in temporary high blood pressure, and may remain high for 6 to 8 hours after infusion with Aliqopa
- For most patients, blood pressure levels typically peak within 2 hours after infusion and then go back to normal

Preparing for your IV treatment:



- **Take your usual medications as you normally would**, unless otherwise directed by your doctors (no premedications are required prior to treatment)



- **Drink plenty of water** the night before and the morning/day of your infusion. It is important to stay hydrated



- **Fasting** (no food, only water) is recommended before your infusion but not required. If you are unable to fast, you will find some healthy meal ideas on the next page



- **Pack a healthy snack.** Bring easy-to-eat snacks in case you get hungry during or after your infusion



- **Entertainment.** Bring a book, tablet, headphones, and a charger for your phone during the infusion

Some examples of meals before treatment:

Breakfast	½ cup low sugar cereal ½ cup milk ½ cup fruit 1 hard boiled egg Beverage (water or decaffeinated tea)	
Lunch	Sandwich: 2 slices of whole-grain bread 4 oz of lean meat, fish, or poultry 1 tsp mayonnaise, lettuce, and tomato slices 1 piece of fruit ½ cup carrot sticks Beverage (water or decaffeinated tea)	
Dinner	4 oz lean meat, fish, or poultry 1 cup steamed vegetables ½ cup grain product (pasta, brown rice) 1 tsp butter Beverage (water or decaffeinated tea)	
Healthy snack examples:	Low-fat or fat-free yogurt 2 tablespoons of peanut butter Low-sugar beverage Dried fruits or nuts	Raw vegetables Whole wheat crackers Low-sugar fruit (eg, berries and watermelon)

What can I expect during and after my IV treatment?

During your IV treatment:



The IV treatment will take 1 hour



Let your healthcare provider know right away if you experience any discomfort during your treatment, including burning, stinging, aching, or feelings of nausea or light-headedness



After your IV treatment:



Stay hydrated. It is important to drink small amounts of water throughout the day



Eat regular, small meals. Choose foods wisely. Fatty, greasy, salty, spicy, or highly seasoned foods may not sit well in your stomach



You may continue with your daily activities, including exercise, depending on your energy level



Minor bruising of the IV site is common and should resolve within a week. If you experience redness, swelling, or pain in the arm or at the injection site, contact your healthcare provider

Avoid taking St. John's wort and drinking grapefruit juice during treatment with Aliqopa™.

Please see additional Important Safety Information throughout this brochure, and [click here](#) for the Consumer Brief Summary of full Prescribing Information.



Bayer is committed to help remove the barriers to patient care

ARC™ is a patient support program that can help

- » Explain your insurance benefits and how they cover Aliqopa treatment
- » Remove barriers insurance coverage for your Aliqopa treatment
- » Identify sources of financial assistance to help you with your out-of-pocket costs

There is a range of resources and services to help you and your healthcare team



CALL

833-ALIQOPA (833-254-7672)
9 AM-7 PM ET, Monday-Friday

Select

- Option 1** for Access Counselors,
- Option 2** for the Aliqopa \$0 Co-Pay Program, or
- Option 3** for Bayer Medical Information



FAX

833-4ARCFAX (833-427-2329)



VISIT

www.aliqopa.com

Bayer is committed to helping you get access to Aliqopa.

If you need help getting your Aliqopa™ treatment, the ARC program offers

- **Bayer Patient Assistance Program** (that provides free drugs) for patients who are uninsured or underinsured and meet certain eligibility criteria*
- **Temporary Patient Assistance Program** for patients whose coverage is delayed or who experience a temporary lapse in coverage. ARC provides free drug during this limited period without coverage
- **Aliqopa \$0 Co-Pay Program** for eligible patients with insurance through an employer or insurance they have purchased themselves (also known as commercial or private insurance)†
- **Referrals to independent assistance foundations** that may be able to help patients with government-sponsored insurance (such as Medicare, Medigap, Medicaid, VA/DoD health plans, and TRICARE) or patients who need help with travel expenses related to their treatment
 - Access Counselors can verify your coverage for Aliqopa and provide information about any available foundations
 - The foundations will determine your eligibility for travel and other supporting assistance based on their own criteria. They will contact you directly about the application process

*Bayer provides Aliqopa free of charge for eligible patients who are uninsured or underinsured. In order to qualify for assistance, you must meet certain eligibility criteria.

†You must not be enrolled in a government-sponsored program, and you must meet certain other eligibility criteria to qualify for this program. If approved, you may pay as little as \$0, with a maximum benefit of \$25,000 per year.

Please see Important Safety Information throughout this brochure, and [click here](#) for the Consumer Brief Summary of full Prescribing Information.

About ALIQOPA (AL-ih-KO-pah)

- ALIQOPA is a prescription medicine used for adults with follicular lymphoma (FL) when the disease has come back after treatment with at least two prior medicines
- ALIQOPA went through a faster FDA approval process because of how it caused FL tumors to shrink. Data gathered from an additional trial may be needed for continued approval of its current use

It is not known if ALIQOPA is safe and effective in children.

Warnings about ALIQOPA

- **Infections:** ALIQOPA can cause serious infections that may lead to death. The most common serious infection was pneumonia. Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with ALIQOPA
- **High blood sugar (hyperglycemia):** High blood sugar is common following ALIQOPA infusion and can sometimes be serious. Tell your healthcare provider if you develop any symptoms of hyperglycemia during treatment with ALIQOPA. Symptoms of hyperglycemia may include:
 - being very hungry
 - headaches
 - being very thirsty
 - frequent urination
- **High blood pressure (hypertension):** High blood pressure is common following ALIQOPA infusion and can sometimes be serious
- **Lung or breathing problems:** Your healthcare provider may do tests to check your lungs if you have breathing problems during treatment with ALIQOPA. Tell your healthcare provider right away if you develop new or worsening cough, shortness of breath, or difficulty breathing
- **Low white blood cell count (neutropenia):** Neutropenia is common with ALIQOPA treatment and can sometimes be serious. Your healthcare provider will check your blood counts regularly during treatment with ALIQOPA. Tell your healthcare provider right away if you have a fever or any signs of infection during treatment with ALIQOPA

- **Severe skin reactions:** Skin peeling, rash, and itching are common with ALIQOPA and can sometimes be serious. Tell your healthcare provider if you develop skin peeling, itching, or rash during treatment with ALIQOPA. Your healthcare provider may withhold treatment, decrease your dose, or permanently stop treatment if you develop severe skin reactions during treatment with ALIQOPA
- **Embryo-fetal toxicity:** ALIQOPA can cause harm to your unborn baby. Effective birth control (contraception) should be used during treatment and for 1 month after the last dose in females of reproductive potential and males with partners of reproductive potential

What should I tell my doctor before taking ALIQOPA?

Before receiving ALIQOPA, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection
- have lung or breathing problems
- have high blood pressure (hypertension)
- have diabetes or high blood sugar (hyperglycemia)
- are pregnant or plan to become pregnant. ALIQOPA can harm your unborn baby
 - Your healthcare provider will perform a pregnancy test before starting treatment with ALIQOPA
 - Females who are able to become pregnant should use effective birth control (contraception) during treatment with ALIQOPA and for 1 month after the last dose of ALIQOPA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with ALIQOPA
 - Males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment with ALIQOPA and for 1 month after the last dose of ALIQOPA

[Click here](#) for additional information from the Consumer Brief Summary of full Prescribing Information.

- are breastfeeding or plan to breastfeed. It is not known if ALIQOPA passes into your breast milk. Do not breastfeed during treatment with ALIQOPA and for 1 month after the last dose of ALIQOPA. Talk to your healthcare provider about the best way to feed your child during treatment with ALIQOPA

What should I ask my doctor before using ALIQOPA?

Tell your healthcare provider about all the medicines you take, including

prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how ALIQOPA works. Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

ALIQOPA should not be taken with strong CYP3A inducers. Dose modification may be needed if taken with strong CYP3A inhibitors

- Examples of strong CYP3A inducers include: carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort.
- Examples of strong CYP3A inhibitors include: boceprevir, clarithromycin, cobicistat, conivaptan, danoprevir and ritonavir, diltiazem, elvitegravir and ritonavir, grapefruit juice, idelalisib, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and ritonavir, nefazodone, nelfinavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir, saquinavir and ritonavir, tipranavir and ritonavir, troleandomycin, voriconazole.

What are the most common side effects of ALIQOPA?

- low white blood cell count (leukopenia and neutropenia)
- low platelets in your blood (thrombocytopenia)
- decreased strength and energy
- lower respiratory tract infection
- nausea
- diarrhea

How do I receive ALIQOPA?

- If ALIQOPA is right for you, your healthcare provider may administer Aliqopa in their office or may refer you to a clinic or facility where healthcare providers or technicians are qualified to give ALIQOPA
- ALIQOPA is given as a 1-hour 60 mg intravenous (IV) infusion on Day 1, Day 8, and Day 15 of a 28-day treatment cycle. This is 1 cycle of treatment.
- Your healthcare provider will decide how many treatment cycles you need. Your healthcare provider may withhold treatment, decrease your dose, temporarily stop, or permanently stop treatment of ALIQOPA if you have certain side effects

The information provided here is not comprehensive.

How to get more information:

- Talk to your healthcare provider or pharmacist
- Visit www.aliqopa.com to obtain the FDA-approved product labeling
- Call 833-Aliqopa (833-254-7672)

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The following organizations may help provide more support during your treatment journey

- Lymphoma Research Foundation
<https://www.lymphoma.org/>
- Leukemia & Lymphoma Society
<http://www.lls.org/>
- Lymphoma Coalition
<https://www.lymphomacoalition.org/>
- Cancer Support Community
<https://www.cancersupportcommunity.org/>
- American Cancer Society
<https://www.cancer.org/>
- CancerCare
<https://www.cancercare.org/>



Your healthcare provider should be your primary resource for information related to your treatment. Talk to your healthcare provider first if you have any questions or need additional information. You can also call 833-ALIQOPA (833-254-7672) or visit aliqopa.com.

Please see Important Safety Information throughout this brochure, and [click here](#) for the Consumer Brief Summary of full Prescribing Information.

 **Aliqopa**[™]
(copanlisib) 60 mg vial
for injection



© 2022 Bayer. All rights reserved.

BAYER, the Bayer Cross, Aliqopa, and ARC are registered trademarks of Bayer.

PP-ALI-US-0748-1 04/22